Examine the data and tweets to deduce if the closing price of $gild will boost or lower at 2017-03-06. Kindly confirm either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-02-17,0.5,1.3,-0.2,-0.7,-0.7,-1.2,-1.3,0.3,0.7,1.1,2.1
2017-02-21,1.0,1.0,-0.7,-0.8,-0.8,0.1,-0.9,0.9,1.4,1.7,2.6
2017-02-22,0.4,1.3,-0.2,-0.7,-0.7,1.1,-0.9,1.2,1.9,2.2,3.0
2017-02-23,-0.9,0.2,-1.4,0.8,0.8,0.2,-1.3,0.1,1.0,1.3,1.9
2017-02-24,-0.9,0.2,-1.3,0.8,0.8,-0.7,-1.5,-0.9,0.1,0.3,0.9
2017-02-27,-1.0,0.1,-1.0,0.8,0.8,-1.3,-1.7,-1.9,-0.8,-0.5,-0.1
2017-02-28,-0.2,0.7,-0.7,-0.0,-0.0,-0.9,-1.3,-2.1,-0.8,-0.5,-0.2
2017-03-01,0.9,1.1,-0.2,-0.4,-0.4,-0.1,-0.5,-1.9,-0.6,-0.1,0.2
2017-03-02,-0.8,0.5,-0.8,0.5,0.5,-0.3,-0.9,-2.1,-1.2,-0.6,-0.4
2017-03-03,-0.1,0.1,-0.7,0.3,0.3,-0.4,-1.1,-1.9,-1.6,-0.9,-0.7

2017-02-17: $gild:us is abbvie the next gilead? #gilead sciences inc   #nasdaq|rx reading: $agn continues deal spree; $immu has trouble sealing deal with $sgen; $mrk and $gild release hiv data |AT_USER thoughts o
2017-02-18: $gild bought low at 65.60.  target is $72|$gild:us better buy: gilead sciences, inc. vs. pfizer inc. #gilead sciences inc   #nasdaq|rt AT_USER #equityresearch top 10 net payout yields for february 201
2017-02-19: 02/17/17 volume leader #74 - gild 11,186,801 gilead sciences inc $gild 69.85 -0.46 -0.65% high today of 70.79  |rt AT_USER investors are betting big against intercept pharmaceuticals. are they wrong? 
2017-02-20: $gild hands off rights to addiction  drug to amygdala neurosciences |rt AT_USER why glaxosmithkline's 2017 guidance is conservative  $gild $jnj $myl $gsk|$gild sum put vol=3,990 sum call vol=8,346 put
2017-02-21: rt AT_USER hepatitis b market: emerging players could make the difference  $abus $gild $gsk $mrk $nvs $sny $v¡­|AT_USER agree $gild not likely, personally i  would hate that but some tweeps made a goo
2017-02-22: 3 things gilead sciences' ceo just said that you'll want to know AT_USER #stocks #biotech $gsk, $gild |#gileadsciences gilead, glaxo pitted in hiv battle; both struggle vs. standard drugs. read more: 
2017-02-23: didn't momelitinib fail? i thought $gild stopped development, no? |rt AT_USER AT_USER a little bird told me $gild is concerned. and filled with lust.|AT_USER a little bird told me $gild is concerned. 
2017-02-24: connor bruggeman schooltrader made $300,000 and he is only 17!   $dis $alxn $noah $gild $qunr|leerink swann comments on gilead sciences, inc.¡¯s fy2021 earnings $gild  #acn|roll untested side of my $g
2017-02-25: rt AT_USER $gild |rt AT_USER wondering if $glpg or $gild will consider cgvhd for filgotinib one day (added to the list in the slide) |rt AT_USER $gild |$gild |i'm sick and tired of gilead sciences: pa
2017-02-27: 10-k $gild $ibb |$gild - statement of changes in beneficial ownership (4) |#biotechs scorching today, $ibb +3% --- i'm long $abbv $abt $bmy $gild $gsk $hqh $hql $lly $nvs $pfe $teva $thw $thq long-ter
2017-03-01: $gild weekly 70c buyer early, but couldn't get it into the gap. keep a eye on this one. |AT_USER AT_USER yes, but the pr they issued is to pump the price. $gild would never issue that.|scan results - 
2017-03-02: valeant: probably worthless, or risky but attractive now?  $abbv $abt $agn $endp $gild $myl $prgo $teva $vrx|rt AT_USER so $gild didnt buy anything with $xbi in the 40-50s .... waiting for lower pps .
2017-03-03: rt AT_USER $gild weekly. initial follow through higher from the inside-inside weeks $ibb |rt AT_USER tgif - yellen and the people's congress #fomc $tza $gild $spy $dia #futures --  |rt AT_USER tgif - 
2017-03-04: AT_USER $gild complain basically after other lower price entry, they can't easily reset list price w/o changing existing contracts.|gilead: oncology acquisition incoming  $glpg $incy $nvs $rhhby $gild
2017-03-05: rt AT_USER AT_USER i've seen $gild for $incy countless times but never $pfe for them. would complement xeljanz and other inflamm¡­|rt AT_USER $gild or $bmrn? |rt AT_USER $incy too big for $gild now, a
Answer:
Fall